MRC Impact Accelerator Award to explore treatment of inflammatory skin conditions
Plasma4 has been awarded an MRC Impact Accelerator project in collaboration with The University of Sheffield, to explore the use of our plasma-materials technology in the treatment of inflammatory skin conditions, such as eczema and psoriasis. Cold atmospheric plasma has previously been shown to reduce inflammation, and, coupled with Plasma4’s hydrogel drug-delivery system, offers the prospect of delivering drugs into the skin in a controlled, sustainable manner to promote healing.
Publication in ACS - Applied Materials & Interfaces
In this research we demonstrate the potential of our unique plasma-materials technology for an on-demand antimicrobials release deep into the tissue. Our composite hydrogel material is versatile and with the action of the plasma jet shows a high antibacterial efficacy against planktonic bacteria and biofilms.
£1.7m project to explore groundbreaking new treatment for biofilm infections in foot ulcers
Plasma4 is delighted to be collaborating with Convatec on developing a plasma-based platform for infected wounds. This study aligns with their scientific strategy for wound care and offers the potential to develop and enhance novel anti-biofilm technologies in order to improve patient care and clinical outcomes
Collaboration with BASF
Plasma4 gratefully acknowledges the support it continues to receive from BASF SE for the development of our composite hydrogel.
